Loading quotes...
Forecast
The analysts' average price target is €1.94 (+2,497.05%). The median is €1.94 (+2,497.05%).
| Buy |
6 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Vivos Therapeutics converts $2.9 million of debt into 11.45 million common shares
On August 31, Vivos Therapeutics entered into twelve exchange agreements with Streeterville Capital and converted outstanding principal claims of $2,861,270 into 11,445,080 common shares at $0.25 each. On August 4 the company had already converted other claims into preferred and common shares; the outstanding balance of the Streeterville note stood at about $3.7 million (including fees and discount) as of August 31. The conversions are intended to reduce liabilities and increase shareholders’ equity; final amounts will be reported in the respective quarterly filing. » More on de.investing.com
Vivos Therapeutics starts joint venture with South Palm for sleep center in Florida
Vivos Therapeutics has reached final agreements with South Palm Cardiovascular Associates to establish a physician-led sleep and airway medicine center in Palm Beach County and plans to hold a majority stake of about 75% through the joint venture AIM Florida LLC. The partners are evaluating locations and lease agreements; patient operations are expected to begin in Q1 2027. An initial "Sleep Optimization Team" for about 250 patients per month is planned; Vivos estimates annual revenue potential of up to $6 million with contribution margins of at least 30%. South Palm is contributing a cardiology practice with roughly 30,000 patients; the offering will include integrated diagnostics and treatments for sleep apnea and cardiovascular patients. » More on de.investing.com
Vivos Therapeutics opens diagnostic and treatment center in Henderson with capacity of over $10 million
Vivos Therapeutics announces the opening of a diagnostic and treatment center in Henderson, Nevada, on August 27. The facility is expected to more than double annual output in Henderson to over $10 million and, at full capacity, employ up to 30 staff. Offered services will include diagnostic testing, clinical evaluations and treatments such as FDA-cleared oral appliances, dental sleep medicine, laser and myofunctional therapy. Vivos expects immediate revenue impact in the Las Vegas market due to increased referrals since May/June. » More on de.investing.com
Vivos Therapeutics reports 35% revenue growth but higher loss and liquidity risk
Vivos Therapeutics reported Q2 2026 revenue up 35% to $5.2m, driven mainly by services from the Sleep Center of Nevada, while net loss widened to $5.5m. Gross margin improved slightly to 57%, but cash stood at only $1.8m and shareholders’ equity falls below Nasdaq’s minimum requirement. Management is pushing the shift to an integrated sleep-medicine model and sees potential positive cash flow in late 2026/early 2027 if new programs like remote monitoring and CPAP services are implemented. Risks remain: large losses, low liquidity and possible delisting if additional financing is not secured. » More on de.investing.com
Vivos Therapeutics reports 35% revenue growth and refocus on sleep centers
Vivos Therapeutics increased revenue in Q2 2026 by 35% to $5.2 million, driven by service revenue from the acquired Sleep Center of Nevada. At the same time, net loss widened to $5.5 million, cash on hand was $1.8 million, and the company warned of doubts about its ability to continue as a going concern and of noncompliance with Nasdaq minimum equity requirements. Management is driving a shift from product sales to integrated sleep centers and expects new programs such as remote patient monitoring and CPAP services to generate positive cash flow by late 2026 or early 2027. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 5.66M | 2.03% |
| Gross profit | 2.93M | 12.79% |
| Net profit | -1.72M | 62.68% |
| EBITDA | -1.25M | 70.65% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.04M |
Number of shares | 13.89M |
52-week high/low | €2.44 - €0.0644 |
| Dividends | No |
Beta | 6.30 |
P/E ratio | -0.05 |
PEG ratio | 0.00 |
P/B ratio | 0.92 |
P/S ratio | 0.06 |
Company profile
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
| Name | VIVOS THERAP. DL-,0001 |
| CEO | R. Kirk Huntsman |
| Headquarters | Littleton,
co USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 12/11/2020 |
| Employees | 268 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | VVOS |